Table 1.
Clinical characteristics of the 26 patients with adrenocortical cancer (ACC) with serum sampled within 3 months after surgery.
| Patient Number |
Age | Sex | Ensat Stage | Mitotane Post-op Adjuvant Therapy |
Recur-rence | Time to Recurrence (Months) |
Death | Time to Death (Months) |
Last Follow-up Without Recurrence or Death (Months) |
Group |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38 | F | I | N | N | - | N | - | 69 | NR3yrs |
| 2 | 30 | F | II | N | N | - | N | - | 5.3 | - |
| 3 | 60 | M | II | N | N | - | N | - | 58 | NR3yrs |
| 4 | 52 | F | II | Y | N | - | N | - | 72 | NR3yrs |
| 5 | 70 | F | II | Y a | N | - | N | - | 80 | NR3yrs |
| 6 | 46 | F | II | Y | N | - | N | - | 87 | NR3yrs |
| 7 | 21 | M | II | Y | N | - | N | - | 65.5 | NR3yrs |
| 8 | 48 | F | III | Y a | N | - | N | - | 57 | NR3yrs |
| 9 | 64 | M | III | N | N | - | N | - | 51 | NR3yrs |
| 10 | 70 | F | III | Y | N | - | N | - | 104 | NR3yrs |
| 11 | 53 | M | III | Y | N | - | N | - | 34 | - |
| 12 | 44 | F | I | N | Y | 57 | N | - | 142 | NR3yrs |
| 13 | 42 | F | II | Y | Y | 50 | N | - | 104 | NR3yrs |
| 14 | 59 | F | II | Y | Y | 5.65 | Y | 12.7 | - | R < 3yrs |
| 15 | 56 | M | II | Y | Y | 2.6 | Y | 13.5 | - | R < 3yrs |
| 16 | 40 | F | II | N b | Y | 9.1 | Y | 38.7 | - | R < 3yrs |
| 17 | 66 | F | II | N b | Y | 17.6 | Y | 41.6 | - | R < 3yrs |
| 18 | 46 | F | II | N b | Y | 13 | Y | 64 | - | R < 3yrs |
| 19 | 42 | M | II | Y | Y | 16 | Y | 65 | - | R < 3yrs |
| 20 | 62 | M | III | Y | Y | 9 | Y | 57 | - | R < 3yrs |
| 21 | 51 | F | III | Y | Y | 3 | Y | 6 | - | R < 3yrs |
| 22 | 78 | F | III | Y | Y | 2.7 | Y | 14.9 | - | R < 3yrs |
| 23 | 37 | M | III | Y | Y | 13 | Y | 30 | - | R < 3yrs |
| 24 | 47 | F | III | Y | Y | 2.6 | Y | 35.5 | - | R < 3yrs |
| 25 | 47 | M | III | Y | Y | 14 | N | - | 119 | R < 3yrs |
| 26 | 43 | F | III | Y | Y | 28.3 | N | - | 116 | R < 3yrs |
NR3yrs: patient with no recurrence after 3 years of post-surgical follow-up. R < 3yrs: patient with a recurrence before 3 years of follow-up. Time to recurrence and time to death were calculated from the date of surgery. F: female; M: male; N: no; Y: yes. a, Among the patients treated post-operatively with mitotane adjuvant therapy, Patients 5 and 8 received mitotane 0.9 and 1.8 months before serum sampling, respectively. All other patients received mitotane after serum sampling including patients 16, 17 and 18 who received palliative mitotane treatment b.